Skip to main content
Premium Trial:

Request an Annual Quote

Clinical Oncology Society Recommends Using Genomic Health's Oncotype DX

NEW YORK (GenomeWeb News) — The American Society of Clinical Oncology recommends using Genomic Health’s Oncotype DX breast cancer assay, according to an updated set of guidelines for using breast cancer tumor markers, the company said today.
 
Oncotype DX is used to predict the likelihood of disease recurrence and whether a node-negative, estrogen-receptor positive tumor will respond to chemotherapy. In its updated guidelines, ASCO recommends using the test and “differentiated it as an optimal tool for breast cancer treatment selection," Steve Shak, chief medical officer at Genomic Health, said in a statement.
 
Genomic Health said ASCO included the test in its updated clinical practice guidelines based on “multiple independent clinical studies involving more than 2,600 breast cancer patients,” including studies published in the New England Journal of Medicine and in the Journal of Clinical Oncology.
 
These guidelines, which serve as “a guide for doctors and outline appropriate methods of treatment,” were published online today in the Journal of Clinical Oncology and will appear in the journal's Nov. 20 print edition, the company added.

The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.